Sugi Predict

Sugi Predict / Compounds / SCHEMBL1276331

SCHEMBL1276331

SCHEMBL1276331

Cc1ccc(NC(=O)c2cc(F)cc(Cl)c2)cc1C(=O)Nc1cccnc1

nearest known ligand 0.76

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 12/20 0.76
▸ CSF1R P07333 8/20 0.68
▸ CYP11B2 P19099 1/20 0.60
▸ KIT P10721 1/20 0.58
▸ KDR P35968 1/20 0.58
▸ MAPK14 Q16539 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3934829 0.92 BRAF (0.83) BRAFCSF1RCYP11B2KITKDR
SCHEMBL3941877 0.92 BRAF (0.83) BRAFCSF1RCYP11B2
SCHEMBL3934893 0.89 CSF1R (0.85) BRAFCSF1RCYP11B2
SCHEMBL3931806 0.89 BRAF (0.78) BRAFCSF1RKITKDRMAPK14
SCHEMBL1276903 0.86 BRAF (1.00) BRAFCSF1RCYP11B2
SCHEMBL3942520 0.86 BRAF (1.00) BRAFCSF1RKITKDRMAPK14
SCHEMBL1276797 0.86 BRAF (0.78) BRAFCSF1RKITKDRMAPK14
SCHEMBL3939472 0.85 BRAF (0.76) BRAFCSF1RCYP11B2KITKDR
SCHEMBL1276598 0.84 BRAF (0.70) BRAFCSF1RKITKDRMAPK14
SCHEMBL3943780 0.84 BRAF (0.73) BRAFCSF1RCYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130280251-A1 Stabilized Angiopoietin-2 Antibodies And Uses Thereof MEDIMMUNE LIMITED (GB) 2013-10-24 — — US claimed
WO-2006067445-A2 CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-06-29 — — WO claimed
US-10329345-B2 Stabilized angiopoietin-2 antibodies and uses thereof MEDIMMUNE LIMITED (GB) 2019-06-25 — — US disclosed
US-20170174756-A1 STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF ASTRAZENECA AB (SE) 2017-06-22 — — US disclosed
US-20130280251-A1 Stabilized Angiopoietin-2 Antibodies And Uses Thereof MEDIMMUNE LIMITED (GB) 2013-10-24 — — US disclosed
US-8507656-B2 Stabilized angiopoietin-2 antibodies and uses thereof MEDIMMUNE LIMITED (GB) 2013-08-13 — — US disclosed
US-20110044998-A1 Stabilized Angiopoietin-2 Antibodies And Uses Thereof MEDIMMUNE LIMITED 2011-02-24 — — US disclosed
EP-1831198-B1 PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2009-04-08 — — EP disclosed
CN-101128454-A Pyridine carboxamide derivatives for use as anticancer agents ASTRAZENECA AB (SE) 2008-02-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174756-A1 STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF TEK, VEGFA, THPO BRAF 2937/4885CSF1R 118/4885CYP11B2 4716/4885
US-20130280251-A1 Stabilized Angiopoietin-2 Antibodies And Uses Thereof TEK, VEGFA, THPO BRAF 2937/4885CSF1R 118/4885CYP11B2 4716/4885
US-10329345-B2 Stabilized angiopoietin-2 antibodies and uses thereof TEK, VEGFA, THPO BRAF 2937/4885CSF1R 118/4885CYP11B2 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.